The KRAS G12 mutation detection rate was similar across the sequencing technologies in the samples with high tumor purity ( > 50th percentile) (RNA-seq, 78.1%; WES, 79.2%; TS, 83.3%). The gene discussed is KRAS; the disease is neoplasm.